Skip to main content
. Author manuscript; available in PMC: 2011 Jul 15.
Published in final edited form as: AIDS. 2010 Oct 23;24(16):2469–2479. doi: 10.1097/QAD.0b013e32833e6d14

Table 3.

Adjusteda hazard odds ratios (aHOR) and 95% confidence intervals (95% CI) virologic and immunologic response to HAART within 24 months following HAART initiation, by regimen class and age, NA-ACCORD, 1998–2008.

aHORa NNRTI 95% CI aHORa Boosted PI 95% CI
Virologic response (HIV RNA ≤500 copies/ml)
Age (years)
 18–<30 Ref - 0.75 0.64–0.88
 30–<40 0.98 0.89–1.07 0.71 0.64–0.79
 40–<50 0.94 0.85–1.03 0.76 0.68–0.85
 50–<60 0.98 0.88–1.09 0.79 0.69–0.90
 ≥60 1.06 0.91–1.24 0.77 0.63–0.94
Immunologic response (≥100 cells/μl increase in CD4 cell count)
Age (years)
 18–<30 Ref - 0.94 0.80–1.11
 30–<40 0.90 0.82–0.99 0.96 0.86–1.07
 40–<50 0.83 0.76–0.91 0.88 0.79–0.99
 50–<60 0.80 0.72–0.90 0.84 0.73–0.96
 ≥60 0.73 0.63–0.85 0.76 0.60–0.97

AIDS acquired immune deficiency syndrome, HAART highly active antiretroviral treatment, HIV human immunodeficiency virus, NNRTI nonnucleoside reverse transcriptase inhibitor, PI protease inhibitor.

a

Pooled logistic regression models weighted for the first change in HAART regimen class (weights at the 1st and 99th percentile were truncated) and adjusted for CD4 cell and HIV viral load at initiation, race and ethnicity, HIV transmission risk group, sex, cohort, clinical AIDS diagnosis prior to HAART initiation, year of HAART initiation and month from HAART initiation.